Neophyr (Nitric Oxide)

Nitric oxide released from Neophyr diffuses into the smooth‑muscle cells of the pulmonary vasculature, where it activates soluble guanylate cyclase. This raises cyclic GMP levels, causing relaxation of the pulmonary arterial smooth muscle and resulting in selective vasodilation that enhances blood flow and oxygen exchange without markedly affecting systemic circulation.

The specific dose of Neophyr is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Dosing regimens are individualized and should follow the guidance of a qualified healthcare professional.

Safety data for Neophyr in pregnant or lactating individuals are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider.

To request Neophyr, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and the necessary import documentation.

The primary alternative to inhaled nitric oxide is inhaled prostacyclin (e.g., iloprost). While both agents provide selective pulmonary vasodilation, nitric oxide has a rapid onset and short half‑life, allowing precise titration, whereas prostacyclin may have a longer duration of action but can be associated with more systemic side effects such as headache and flushing.

Neophyr should be stored at ambient temperature, kept in its original sealed container, and protected from moisture and direct sunlight. Ensure the delivery system remains clean and free from contamination, and follow any manufacturer‑provided handling instructions to maintain product stability.

Neophyr is delivered via a calibrated inhalation system that introduces nitric oxide gas directly into the patient’s breathing circuit. Administration is performed by trained healthcare personnel, who adjust the flow rate to achieve the prescribed concentration while continuously monitoring the patient’s oxygenation and hemodynamic status.

The most serious adverse events associated with Neophyr include methemoglobinemia, which impairs oxygen delivery; rebound pulmonary hypertension that can occur after abrupt discontinuation; and severe systemic hypotension. Prompt recognition and appropriate monitoring are essential to mitigate these risks.

Neophyr is contraindicated in patients with known hypersensitivity to nitric oxide or any component of the delivery system. It should also be avoided in individuals with severe left‑heart failure, significant hypoxemia unresponsive to oxygen therapy, or those in whom the risk of methemoglobinemia cannot be adequately monitored.